Naturally occurring anti-cancer agents targeting EZH2

Cancer Letters

Volumn 400, Issue , 2017, Pages 325-335

  Shahabipour, Fahimeh ^a   Caraglia, Michele ^b   Majeed, Muhammed ^c   Derosa, Giuseppe ^d,e   Maffioli, Pamela ^d,e   Sahebkar, Amirhossein ^f  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Sabinsa Inc   (United States)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Chemosensitization; EZH2; Natural compounds; Polycomb proteins; PRC2

Indexed keywords

3 DEAZANEPLANOCIN A; ANTINEOPLASTIC AGENT; BERBERINE; CURCUMIN; DAVIDIIN; EPIGALLOCATECHIN GALLATE; GAMBOGIC ACID; HERBACEOUS AGENT; JASMONIC ACID METHYL ESTER; RESVERATROL; SINECATECHINS; SULFORAPHANE; TANSHINDIOL C; TRANSCRIPTION FACTOR EZH2; TRIPTOLIDE; UNCLASSIFIED DRUG; URSOLIC ACID; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN;

ALCEA ROSEA; APOPTOSIS; CANCER CELL; CANCER INHIBITION; DOWN REGULATION; DRUG TARGETING; HUMAN; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; HALF LIFE TIME; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; ENZYME INHIBITORS; HALF-LIFE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85017344251     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.03.020     Document Type: Review

References (135)

1. [1] Jones, P.A., Baylin, S.B., The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:6 (2002 Jun), 415–428.
2. [2] Baylin, S.B., Ohm, J.E., Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6:2 (2006 Feb), 107–116.
3. [3] Ting, A.H., McGarvey, K.M., Baylin, S.B., The cancer epigenome–components and functional correlates. Genes Dev. 20:23 (2006 Dec 1), 3215–3231 Sparmann A1, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006 Nov;6(11):846-56.
4. [4] Moss, T.J., Wallrath, L.L., Connections between epigenetic gene silencing and human disease. Mutat. Res. 618 (2007), 163–174.
5. [5] Laugesen, A., Helin, K., Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14 (2014), 735–751.
6. [6] Simon, J.A., Lange, C.A., Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647 (2008), 21–29.
7. [7] Michalak, E.M., Visvader, J.E., Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?. Mol Oncol 10:10 (2016 Dec), 1497–1515, 10.1016/j.molonc.2016.09.003 Epub 2016 Sep. 23.
8. [8] Matsukawa, Y., Semba, S., Kato, H., Ito, A., Yanagihara, K., Yokozaki, H., Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97 (2006), 484–491.
9. [9] Collett, K., Eide, G.E., Arnes, J., Stefansson, I.M., Eide, J., Braaten, A., et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 12 (2006), 1168–1174.
10. [10] Choi, S.W., Friso, S., Epigenetics: a new bridge between nutrition and health. Adv. Nutr. 1:1 (2010 Nov), 8–16, 10.3945/an.110.1004 Epub 2010 Nov 16.
11. [11] Kim, K.H., Roberts, C.W., Targeting EZH2 in cancer. Nat. Med. 22 (2016), 128–134.
12. [12] Tonini, T., D'Andrilli, G., Fucito, A., Gaspa, L., Bagella, L., Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J. Cell. Physiol. 214 (2008), 295–300.
13. [13] Xie, H., Xu, J., Hsu, J.H., Nguyen, M., Fujiwara, Y., Peng, C., et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 14 (2014), 68–80.
14. [14] Momparler, R.L., Idaghdour, Y., Marquez, V.E., Momparler, L.F., Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. Leuk. Res. 36 (2012), 1049–1054.
15. [15] Kuzmichev, A., Jenuwein, T., Tempst, P., Reinberg, D., Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol. Cell 14 (2004), 183–193.
16. [16] Pasini, D., Malatesta, M., Jung, H.R., Walfridsson, J., Willer, A., Olsson, L., et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic acids Res. 38 (2010), 4958–4969.
17. [17] Chase, A., Cross, N.C., Aberrations of EZH2 in cancer. Clin. Cancer Res. 17 (2011), 2613–2618.
18. [18] Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42 (2010), 181–185.
19. [19] Fujikawa, D., Nakagawa, S., Hori, M., Kurokawa, N., Soejima, A., Nakano, K., et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127 (2016), 1790–1802.
20. [20] Pan, X., Papasani, M., Hao, Y., Calamito, M., Wei, F., Quinn, W.J., et al. YY1 controls Igκ repertoire andB-cell development, and localizes with condensin on the Igκ locus. EMBO J. 32 (2013), 1168–1182.
21. [21] Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002), 624–629.
22. [22] Sparmann, A., van Lohuizen, M., Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6 (2006), 846–856.
23. [23] Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A.S., et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 72 (2012), 335–345.
24. [24] Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23 (2013), 839–852.
25. [25] Khan, S., Jankowska, A., Mahfouz, R., Dunbar, A., Sugimoto, Y., Hosono, N., et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 27 (2013), 1301–1309.
26. [26] Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E., Helin, K., EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22 (2003), 5323–5335.
27. [27] Bruggeman, S.W., Valk-Lingbeek, M.E., van der Stoop, P.P., Jacobs, J.J., Kieboom, K., Tanger, E., et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes & Dev. 19 (2005), 1438–1443.
28. [28] Xu, K., Wu, Z.J., Groner, A.C., He, H.H., Cai, C., Lis, R.T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338 (2012), 1465–1469.
29. [29] Higa, L.A., Wu, M., Ye, T., Kobayashi, R., Sun, H., Zhang, H., CUL4–DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat. Cell Biol. 8 (2006), 1277–1283.
30. [30] Lee, J.M., Lee, J.S., Kim, H., Kim, K., Park, H., Kim, J.-Y., et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol. Cell 48 (2012), 572–586.
31. [31] Gall Troselj, K., Novak Kujundzic, R., Ugarkovic, D., Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background. Clin. Epigenetics, 8, 2016, 55.
32. [32] D'Angelo, V., Iannotta, A., Ramaglia, M., Lombardi, A., Zarone, M., Desiderio, V., et al. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitablemolecular target in combination treatment approaches. J. Exp. Clin. Cancer Res., 34, 2015, 1.
33. [33] Ramaglia, M., D'Angelo, V., Iannotta, A., Pinto, D., Pota, E., Affinita, M.C., et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int., 16, 2016, 59.
34. [34] Glazer, R.I., Hartman, K.D., Knode, M.C., Richard, M.M., Chiang, P.K., Tseng, C.K., et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun. 135 (1986), 688–694.
35. [35] Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P.L., et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Dev. 21 (2007), 1050–1063.
36. [36] Miranda, T.B., Cortez, C.C., Yoo, C.B., Liang, G., Abe, M., Kelly, T.K., et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. cancer Ther. 8 (2009), 1579–1588.
37. [37] Knutson, S.K., Wigle, T.J., Warholic, N.M., Sneeringer, C.J., Allain, C.J., Klaus, C.R., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8 (2012), 890–896.
38. [38] McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492 (2012), 108–112.
39. [39] Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. 109 (2012), 21360–21365.
40. [40] Konze, K.D., Ma, A., Li, F., Barsyte-Lovejoy, D., Parton, T., MacNevin, C.J., et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8 (2013), 1324–1334.
41. [41] Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. 110 (2013), 7922–7927.
42. [42] Kim, W., Bird, G.H., Neff, T., Guo, G., Kerenyi, M.A., Walensky, L.D., et al. Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9 (2013), 643–650.
43. [43] Kumar, B., Singh, V., Shankar, R., Kumar, K., Rawal, R., Synthetic and medicinal prospective of structurally modified curcumins. Curr. Top. Med. Chem., 2016.
44. [44] Maheshwari, R.K., Singh, A.K., Gaddipati, J., Srimal, R.C., Multiple biological activities of curcumin: ashort review. Life Sci. 78 (2006), 2081–2087.
45. [45] Shen, L., Liu, C.-C., An, C.-Y., Ji, H.-F., How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. Sci. Rep., 6, 2016.
46. [46] Momtazi, A.A., Shahabipour, F., Khatibi, S., Johnston, T.P., Pirro, M., Sahebkar, A., Curcumin as a MicroRNA regulator in cancer: a review. Rev. Physiol., Biochem. Pharmacol. 171 (2016), 1–38.
47. [47] Mirzaei, H., Naseri, G., Rezaee, R., Mohammadi, M., Banikazemi, Z., Mirzaei, H.R., et al. Curcumin: a new candidate for melanoma therapy?. Int. J. cancer 139 (2016), 1683–1695.
48. [48] Momtazi, A.A., Sahebkar, A., Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr. Pharm. Des. 22 (2016), 4386–4397.
49. [49] Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., Ghayour-Mobarhan, M., et al. Effects of supplementation with curcuminoidson dyslipidemia in obese patients: a randomized crossover trial. Phytother. Res. PTR 27 (2013), 374–379.
50. [50] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement. Ther. Med. 22 (2014), 851–857.
51. [51] Sahebkar, A., Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 39 (2013), 197–208.
52. [52] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia, Nature reviews. Cardiology, 11, 2014, 123.
53. [53] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Majeed, M., Sahebkar, A., Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin. Nutr. 34 (2015), 1101–1108.
54. [54] Panahi, Y., Sahebkar, A., Parvin, S., Saadat, A., A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem. 49 (2012), 580–588.
55. [55] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. PTR 28 (2014), 633–642.
56. [56] Derosa, G., Maffioli, P., Simental-Mendia, L.E., Bo, S., Sahebkar, A., Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 111 (2016), 394–404.
57. [57] Ganjali, S., Sahebkar, A., Mahdipour, E., Jamialahmadi, K., Torabi, S., Akhlaghi, S., et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. TheScientificWorldJournal, 2014, 2014, 898361.
58. [58] Ghandadi, M., Sahebkar, A., Curcumin: an effective inhibitor of interleukin-6. Curr. Pharm. Des., 2016.
59. [59] Karimian, M.S., Pirro, M., Majeed, M., Sahebkar, A., Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine & growth factor Rev., 2016.
60. [60] Sahebkar, A., Cicero, A.F., Simental-Mendia, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 107 (2016), 234–242.
61. [61] Panahi, Y., Rahimnia, A.R., Sharafi, M., Alishiri, G., Saburi, A., Sahebkar, A., Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother. Res. PTR 28 (2014), 1625–1631.
62. [62] Sahebkar, A., Henrotin, Y., Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med. 17 (2016), 1192–1202.
63. [63] Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., et al. An investigation of theeffects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin. J. Integr. Med. 21 (2015), 332–338.
64. [64] Panahi, Y., Badeli, R., Karami, G.R., Sahebkar, A., Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res. PTR 29 (2015), 17–21.
65. [65] Sahebkar, A., Serban, M.C., Ursoniu, S., Banach, M., Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J. Funct. Foods 18 (2015), 898–909.
66. [66] Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., Iranshahi, M., et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother. Res. PTR 27 (2013), 1883–1888.
67. [67] Panahi, Y., Sahebkar, A., Amiri, M., Davoudi, S.M., Beiraghdar, F., Hoseininejad, S.L., et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 108 (2012), 1272–1279.
68. [68] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E., Sahebkar, A., Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol. 68 (2016), 223–229.
69. [69] Zabihi, N.A., Pirro, M., Johnston, T.P., Sahebkar, A., Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr. Pharm. Des., 2016.
70. [70] Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother. Res. PTR 30 (2016), 1540–1548.
71. [71] Liu, W., Zhai, Y., Heng, X., Che, F.Y., Chen, W., Sun, D., et al. Oral bioavailability of curcumin: problems and advancements. J. drug Target. 24 (2016), 694–702.
72. [72] Momtazi, A.A., Sahebkar, A., Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr. Pharm. Des., 2016.
73. [73] Colacino, J.A., McDermott, S.P., Sartor, M.A., Wicha, M.S., Rozek, L.S., Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention. Breast Cancer Res. Treat., 2016, 1–13.
74. [74] Hua, W.-F., Fu, Y.-S., Liao, Y.-J., Xia, W.-J., Chen, Y.-C., Zeng, Y.-X., et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol. 637 (2010), 16–21.
75. [75] Mimeault, M., Batra, S.K., Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin. Med., 6, 2011, 8546.
76. [76] Toden, S., Okugawa, Y., Jascur, T., Wodarz, D., Komarova, N.L., Buhrmann, C., et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis 36 (2015), 355–367.
77. [77] Wu, G.-Q., Chai, K.-Q., Zhu, X.-M., Jiang, H., Wang, X., Xue, Q., et al. Anti-cancer effects of curcumin on lung cancer through the inhibitionof EZH2 and NOTCH1. Oncotarget, 2016.
78. [78] Kim, K.H., Roberts, C.W., Targeting EZH2 in cancer. Nat. Med. 22 (2016), 128–134.
79. [79] Johnston, P., Kaye, S., Capecitabine: a novel agent for the treatment of solid tumors. Anti-cancer drugs 12 (2001), 639–646.
80. [80] Cano, A., Pérez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G., et al. The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2 (2000), 76–83.
81. [81] Mani, S.A., Guo, W., Liao, M.-J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
82. [82] Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, N.V., et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome inbreast, ovarian, and pancreatic cancers. Mol. Carcinog. 47 (2008), 701–706.
83. [83] Jiang, M., Huang, O., Zhang, X., Xie, Z., Shen, A., Liu, H., et al. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules 18 (2013), 701–720.
84. [84] Zhang, B., Pan, X., Cobb, G.P., Anderson, T.A., microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302 (2007), 1–12.
85. [85] Bao, B., Ali, S., Ahmad, A., Azmi, A.S., Li, Y., Banerjee, S., et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One, 7, 2012, e50165.
86. [86] Shimizu, M., Fukutomi, Y., Ninomiya, M., Nagura, K., Kato, T., Araki, H., et al. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol. Biomark. Prev. 17 (2008), 3020–3025.
87. [87] Toden, S., Tran, H.-M., Tovar-Camargo, O.A., Okugawa, Y., Goel, A., Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget 7 (2016), 16158–16171.
88. [88] Mills, A.A., Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 10 (2010), 669–682.
89. [89] Tang, S.N., Fu, J., Nall, D., Rodova, M., Shankar, S., Srivastava, R.K., Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int. J. Cancer 131 (2012), 30–40.
90. [90] Kim, J., Zhang, X., Rieger-Christ, K.M., Summerhayes, I.C., Wazer, D.E., Paulson, K.E., et al. Suppression of Wnt signaling bythe green tea compound EGCG in breast cancer and the requirement for the HBP1 transcriptional repressor. Cancer Res., 66, 2006 30–30.
91. [91] Deb, G., Thakur, V.S., Limaye, A.M., Gupta, S., Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells. Mol. Carcinog. 54 (2015), 485–499.
92. [92] Schor, S.L., Schor, A.M., Tumour-stroma interactions: phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res., 3, 2001, 1.
93. [93] Brew, K., Nagase, H., The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta (BBA)-Molecular Cell Res. 1803 (2010), 55–71.
94. [94] Zhang, L., Zhao, L., Zhao, D., Lin, G., Guo, B., Li, Y., et al. Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3. Cancer gene Ther. 17 (2010), 171–179.
95. [95] Choudhury, S.R., Balasubramanian, S., Chew, Y.C., Han, B., Marquez, V.E., Eckert, R.L., (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis, 2011 bgr171.
96. [96] Balasubramanian, S., Adhikary, G., Eckert, R.L., The Bmi-1 polycomb protein antagonizes the (−)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 31 (2010), 496–503.
97. [97] Chiang, P.K., Burbelo, P.D., Brugh, S.A., Gordon, R., Fukuda, K., Yamada, Y., Activation of collagen IV gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs. Indirect inhibitors of methylation. J. Biol. Chem. 267 (1992), 4988–4991.
98. [98] Kalushkova, A., Fryknäs, M., Lemaire, M., Fristedt, C., Agarwal, P., Eriksson, M., et al. Polycomb target genes are silenced in multiple myeloma. PLoS One, 5, 2010, e11483.
99. [99] Chen, B.J., Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk. lymphoma 42 (2001), 253–265.
100. [100] Meng, C., Zhu, H., Song, H., Wang, Z., Huang, G., Li, D., et al. Targets and molecular mechanisms of triptolide in cancer therapy. Chin. J. cancer Res. = Chung-kuo yen cheng yen chiu 26 (2014), 622–626.
101. [101] Zhao, F., Chen, Y., Zeng, L., Li, R., Zeng, R., Wen, L., et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histonemethylation in multiple myeloma U266 cells. Eur. J. Pharmacol. 646 (2010), 1–11.
102. [102] Zhao, F., Chen, Y., Li, R., Liu, Y., Wen, L., Zhang, C., Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology 267 (2010), 70–79.
103. [103] Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S.K., Reczek, E.E., De Raedt, T., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 16 (2010), 286–294.
104. [104] Tamgue, O., Chai, C.S., Hao, L., Zambe, J.C., Huang, W.W., Zhang, B., et al. Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pac. J. cancer Prev. APJCP 14 (2013), 5663–5669.
105. [105] Shanmugam, M.K., Dai, X., Kumar, A.P., Tan, B.K., Sethi, G., Bishayee, A., Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem. Pharmacol. 85 (2013), 1579–1587.
106. [106] Kim, J.H., Kim, Y.H., Song, G.Y., Kim, D.E., Jeong, Y.J., Liu, K.H., et al. Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of beta-catenin degradation. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 67 (2014), 87–95.
107. [107] Deng, L., Zhang, R., Tang, F., Li, C., Xing, Y.Y., Xi, T., Ursolic acid induces U937 cells differentiation by PI3K/Akt pathway activation. Chin. J. Nat. Med. 12 (2014), 15–19.
108. [108] Wu, J., Zhao, S., Tang, Q., Zheng, F., Chen, Y., Yang, L., et al. Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells. J. Exp. Clin. cancer Res. CR, 34, 2015, 99.
109. [109] Zhang, X.L., Lu, X., Geng, W., Qu, G.W., Zhou, Z.Y., Jiang, L.H., et al. Role of glycol chitosan-incorporated ursolic acid nanoparticles in the treatment of osteosarcoma. Trop. J. Pharm. Res. 14 (2015), 1581–1588.
110. [110] van Poppel, G., Verhoeven, D.T., Verhagen, H., Goldbohm, R.A., Brassica vegetables and cancer prevention. Epidemiology and mechanisms. Adv. Exp. Med. Biol. 472 (1999), 159–168.
111. [111] Balasubramanian, S., Chew, Y.C., Eckert, R.L., Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells. Mol. Pharmacol. 80 (2011), 870–878.
112. [112] Fisher, M.L., Adhikary, G., Grun, D., Kaetzel, D.M., Eckert, R.L., The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Mol. Carcinog., 2015.
113. [113] Novelle, M.G., Wahl, D., Dieguez, C., Bernier, M., de Cabo, R., Resveratrol supplementation: where are we now and where should we go?. Ageing Res. Rev. 21 (2015), 1–15.
114. [114] Ren, X., Bai, X., Zhang, X., Li, Z., Tang, L., Zhao, X., et al. Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells. Mol. Cell. Proteom. MCP 14 (2015), 316–328.
115. [115] Chang, Y.C., Lin, C.W., Yu, C.C., Wang, B.Y., Huang, Y.H., Hsieh, Y.C., et al. Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression. Oncotarget 7 (2016), 12137–12149.
116. [116] Liao, S.-G., Zhang, L.-J., Sun, F., Zhang, J.-J., Chen, A.-Y., Lan, Y.-Y., et al. Antibacterial and anti-inflammatory effects of extracts and fractions from Polygonum capitatum. J. Ethnopharmacol. 134 (2011), 1006–1009.
117. [117] Wang, Y., Ma, J., Chow, S.C., Li, C.H., Xiao, Z., Feng, R., et al. A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2. Tumor Biol. 35 (2014), 205–212.
118. [118] Zhou, L., Zuo, Z., Chow, M.S.S., Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45 (2005), 1345–1359.
119. [119] Woo, J., Kim, H.-Y., Byun, B.J., Chae, C.-H., Lee, J.Y., Ryu, S.Y., et al. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors. Bioorg. Med. Chem. Lett. 24 (2014), 2486–2492.
120. [120] Yu, J., Guo, Q.-L., You, Q.-D., Zhao, L., Gu, H.-Y., Yang, Y., et al. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylationof CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28 (2006), 632–638.
121. [121] Wu, Z.-Q., Guo, Q.-L., You, Q.-D., Zhao, L., Gu, H.-Y., Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and repressestelomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol. Pharm. Bull. 27 (2004), 1769–1774.
122. [122] Yi, T., Yi, Z., Cho, S.-G., Luo, J., Pandey, M.K., Aggarwal, B.B., et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 68 (2008), 1843–1850.
123. [123] Rong, J.-J., Hu, R., Song, X.-M., Ha, J., Lu, N., Qi, Q., et al. Gambogic acid triggers DNAdamage signaling that induces p53/p21 Waf1/CIP1 activation through the ATR-Chk1 pathway. Cancer Lett. 296 (2010), 55–64.
124. [124] Milrot, E., Jackman, A., Flescher, E., Gonen, P., Kelson, I., Keisari, Y., et al. Enhanced killing of cervical cancer cells bycombinations of methyl jasmonate with cisplatin, X or alpha radiation. Investig. new drugs 31 (2013), 333–344.
125. [125] Jiang, G., Zhao, J., Xiao, X., Tao, D., Gu, C., Tong, Q., et al. AN N-terminal Smac peptide sensitizes human prostatecarcinoma cells to methyl jasmonate-induced apoptosis. Cancer Lett. 302 (2011), 37–46.
126. [126] Weikert, S., Christoph, F., Kollermann, J., Muller, M., Schrader, M., Miller, K., et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16 (2005), 349–354.
127. [127] Wang, Y., Xiang, W., Wang, M., Huang, T., Xiao, X., Wang, L., et al. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101. Br. J. Pharmacol. 171 (2014), 618–635.
128. [128] Ahmadi, M., Rad, A.K., Rajaei, Z., Hadjzadeh, M.A.R., Mohammadian, N., Tabasi, N.S., Alcea rosea root extract as a preventive and curative agent in ethylene glycol-induced urolithiasis in rats. Indian J. Pharmacol. 44 (2012), 304–307.
129. [129] Ahmed, I., Roy, B.C., Subramaniam, D., Ganie, S.A., Kwatra, D., Dixon, D., et al. An ornamental plant targets epigenetic signaling to block cancer stem cell-driven colon carcinogenesis. Carcinogenesis 37 (2015), 385–396.
130. [130] Chen, S.Z., Chen, X.M., Li, Y.Q., Zhang, F., Yang, S., Mo, K.L., et al. Inhibitory effectof berberine on zeste homolog 2 (Ezh2) enhancement in human esophageal cell lines. Trop. J. Pharm. Res. 14 (2015), 1589–1595.
131. [131] Choudhury, S.R., Balasubramanian, S., Chew, Y.C., Han, B., Marquez, V.E., Eckert, R.L., (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32 (2011), 1525–1532.
132. [132] Takashina, T., Kinoshita, I., Kikuchi, J., Shimizu, Y., Sakakibara-Konishi, J., Oizumi, S., et al. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Cancer Sci. 107:7 (2016), 955–962.
133. [133] Wang, S.H., Lin, P.Y., Chiu, Y.C., Huang, J.S., Kuo, Y.T., Wu, J.C., et al. Curcumin-mediated HDAC inhibition suppresses the DNA damage response and contributes to increased DNA damage sensitivity. PLoS One, 10(7), 2015 Jul 28, e0134110.
134. [134] Dickinson, S.E., Rusche, J.J., Bec, S.L., Horn, D.J., Janda, J., Rim, S.H., et al. The effect of sulforaphane on histone deacetylase activity in keratinocytes: differences between in vitro and in vivo analyses. Mol. Carcinog. 54:11 (2015 Nov), 1513–1520.
135. [135] Ganai, S.A., Rashid, R., Abdullah, E., Altaf, M., Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer. Anticancer Agents Med Chem, 2016 Jun 6 [Epub ahead of print].